Insider trades
Open-market buys and sales that US company officers, directors and 10% owners file, newest filing first.
| Trade type | ||||||||
|---|---|---|---|---|---|---|---|---|
MoonLake ImmunotherapeuticsMLTX | Open-market sale10b5-1 plan | 06/22 | 06/23 | 39,120 sh | $22.04 | $862,204.8 | −3.4% | |
MoonLake ImmunotherapeuticsMLTX | Open-market sale10b5-1 plan | 06/17–06/18 | 06/18 | 17,876 sh2 trades | $19.67avg. | $351,576.16 | −1.5% | |
MoonLake ImmunotherapeuticsMLTX | Open-market sale10b5-1 plan | 06/15–06/17 | 06/17 | 150,000 sh3 trades | $19.01avg. | $2,851,000 | −5.0% | |
MoonLake ImmunotherapeuticsMLTX | Open-market sale10b5-1 plan | 05/11 | 05/13 | 13,653 sh | $20.02 | $273,333.06 | −1.2% | |
MoonLake ImmunotherapeuticsMLTX | Open-market sale10b5-1 plan | 04/14 | 04/16 | 2,426 sh | $19.56 | $47,452.56 | −0.2% | |
MoonLake ImmunotherapeuticsMLTX | Open-market sale | 04/10–04/13 | 04/14 | 150,000 sh2 trades | $18.35avg. | $2,752,162.86 | −4.9% | |
MoonLake ImmunotherapeuticsMLTX | Open-market sale10b5-1 plan | 04/09–04/10 | 04/10 | 87,795 sh2 trades | $18.95avg. | $1,663,934.55 | −6.9% | |
MoonLake ImmunotherapeuticsMLTX | Open-market sale | 03/31 | 04/02 | 3,750,000 sh3 trades | $16.79avg. | $62,962,500 | −78.3% | |
MoonLake ImmunotherapeuticsMLTX | Open-market sale | 25/12/08–25/12/09 | 25/12/10 | 200,000 sh2 trades | $14.87avg. | $2,974,700 | −6.5% | |
MoonLake ImmunotherapeuticsMLTX | Open-market sale | 25/12/08–25/12/09 | 25/12/10 | 202,908 sh2 trades | $14.85avg. | $3,012,462.44 | −100.0% | |
MoonLake ImmunotherapeuticsMLTX | Open-market buy | 25/10/08 | 25/10/09 | 10,870 sh | $9.09 | $98,808.3 | +1.8% | |
MoonLake ImmunotherapeuticsMLTX | Open-market sale | 25/09/29–25/09/30 | 25/10/01 | 6,499,978 sh5 trades | $7.21avg. | $46,868,184.1 | −76.5% | |
Catherine MoukheibirDirector | MoonLake ImmunotherapeuticsMLTX | Open-market sale | 25/07/03 | 25/07/07 | 23,500 sh | $48.79 | $1,146,565 | −100.0% |
MoonLake ImmunotherapeuticsMLTX | Open-market sale | 24/10/04 | 24/10/08 | 2,000,000 sh3 trades | $50.00avg. | $100,000,000 | −60.8% | |
Simon SturgeDirector | MoonLake ImmunotherapeuticsMLTX | Open-market sale | 24/10/04 | 24/10/08 | 171,000 sh | $53.72 | $9,186,120 | −49.9% |
MoonLake ImmunotherapeuticsMLTX | Open-market sale10b5-1 plan | 24/02/27–24/02/29 | 24/02/29 | 123,615 sh3 trades | $55.03avg. | $6,803,043.6 | −4.0% | |
MoonLake ImmunotherapeuticsMLTX | Open-market sale10b5-1 plan | 24/02/27–24/02/28 | 24/02/29 | 118,922 sh4 trades | $55.00avg. | $6,540,710 | No record | |
MoonLake ImmunotherapeuticsMLTX | Open-market sale10b5-1 plan | 24/02/21 | 24/02/23 | 1,125 sh | $55.27 | $62,178.75 | −0.0% | |
MoonLake ImmunotherapeuticsMLTX | Open-market sale10b5-1 plan | 24/02/20–24/02/21 | 24/02/22 | 21,078 sh4 trades | $57.33avg. | $1,208,418.49 | No record | |
MoonLake ImmunotherapeuticsMLTX | Open-market sale10b5-1 plan | 24/02/15–24/02/20 | 24/02/20 | 60,000 sh3 trades | $59.26avg. | $3,555,400 | −1.9% |